Amgen to Webcast 2011 Business Review Meeting on April 21

THOUSAND OAKS, Calif., April 14, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced that it will hold its Business Review Meeting on Thursday, April 21, 2011 at the Mandarin Oriental Hotel, 80 Columbus Circle, New York City, beginning at 8 a.m. Eastern Time. In the meeting, Kevin Sharer, chairman and CEO, Robert A. Bradway, president and COO, Roger M. Perlmutter, M.D., Ph.D., executive vice president, Research and Development, and Jonathan M. Peacock, executive vice president and CFO, will discuss the Company's strategy and long-term growth objectives, commercial performance and expectations, research and development innovation and pipeline progress, financial performance expectations and the Company's capital allocation plan.

The webcast will be available to members of the news media, investors and the general public and is expected to last approximately three hours.

The webcast of the meeting, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability, and webcast links are noted on Amgen's Investor Relations Events Calendar.  The webcast will be archived and available for replay at least 30 days after the event.

About Amgen

Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com.

CONTACT: Amgen, Thousand Oaks
David Polk, 805-447-4613 (media)
Arvind Sood, 805-447-1060 (investors)

(Logo:  http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)

SOURCE Amgen

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.